Babcock stock rises as buyback data, Artisan stake put Type 31 gap in focus

Babcock stock rises as buyback data, Artisan stake put Type 31 gap in focus

July 7, 2026

London, July 7, 2026, 19:03 BST

  • Babcock ended at 1,079p, up 2.96%, while the FTSE 100 rose 0.13%.
  • The latest buyback entry was small: 14,344 shares on July 6, with 217,540 bought since July 1.
  • Artisan Partners moved above 5% of voting rights; the Type 31 frigate charge is still the number that frames the stock.

Babcock International Group PLC (LON:BAB) rose 2.96% to 1,079p in London on Tuesday, closing at its session high and beating a 0.13% rise in the FTSE 100 Index (INDEXFTSE:UKX). The stock is 19.6% above its June 29 intraday low of 902.4p, but still 29.3% below its 52-week high of 1,527p.

The trade was not built on a fresh order announcement. Babcock’s RNS feed for July 7 and July 6 showed a buyback notice and a holding notice, not a contract award or trading update. That puts the focus on ownership, buyback timing and the market’s read-through from last month’s Type 31 charge.

Babcock said it bought 14,344 shares on July 6 at an average price of £10.4430. Since July 1, it has bought 217,540 shares for £2.18 million and holds the shares in treasury. That is about 0.04% of the 490.2 million shares in issue after treasury stock, so Tuesday’s 31p gain was not a mechanical buyback move alone.

Artisan Partners Limited Partnership crossed a 5% notification line, with 24.85 million voting rights, or 5.07%, up from 4.98% at the prior filing. The notice said Artisan held the position as discretionary investment manager. It did not link the change to activism.

Investing.com daily data put Babcock up 17.2% from its June 29 close, with two sharp up days on July 1 and July 2 and another 2.96% gain on Tuesday.

DateCloseDaily moveVolume
Jun 29921.0p-5.15%8.75 mln
Jun 30951.8p+3.34%3.73 mln
Jul 11,001.0p+5.17%3.45 mln
Jul 21,056.5p+5.54%2.73 mln
Jul 31,039.0p-1.66%1.23 mln
Jul 61,048.0p+0.87%1.17 mln
Jul 71,079.0p+2.96%5.56 mln

Peer prices made Babcock’s session stand out. BAE Systems PLC and Rolls-Royce Holdings PLC fell, QinetiQ Group PLC (LON:QQ) rose less, and Chemring Group PLC (LON:CHG) was little changed.

Stock or indexJuly 7 moveQuoted level
Babcock International Group PLC (LON:BAB)+2.96%1,079.0p
BAE Systems PLC -2.67%1,976p/1,977p
QinetiQ Group PLC (LON:QQ)+0.99%487.0p/487.6p
Chemring Group PLC (LON:CHG)-0.18%564.5p/565.5p
Rolls-Royce Holdings PLC -3.74%1,447.6p/1,448.2p
FTSE 100 Index (INDEXFTSE:UKX)+0.13%10,665.88

The old problem is still Type 31. In June, Babcock booked a £140 million charge on the Royal Navy frigate programme. Underlying operating profit fell to £293.3 million from £362.9 million. Excluding Type 31, underlying operating profit would have been £433.3 million and the margin 8.2%.

That split matters for the share price. Babcock has a cash-return story, but the re-rating case still rests on contract execution. The company said fiscal 2027 started with about 70% of expected revenue under contract, and it kept medium-term guidance for average mid-single-digit organic revenue growth and an underlying operating margin of at least 9%.

Babcock FY26 lineConfirmed figureMarket read
Type 31 charge£140 mlnMarine contract risk remains in the price
Underlying operating profit£293.3 mlnDown from £362.9 mln
Underlying operating profit excluding Type 31£433.3 mlnCore margin nearer the target range
Underlying free cash flow£261.8 mlnSupports buyback and dividend capacity
Contract backlog£9.8 blnDown from £10.4 bln
New buyback plan£200 mlnSpread across FY27, not a one-day prop

Chief Executive David Lockwood said in the June results that Babcock had made “continued strategic and operational progress” and would “remain on track to deliver our medium-term guidance.” The market is now testing that against the Marine margin line, where the statutory operating loss was £28.4 million in fiscal 2026 but would have been a £110.2 million underlying profit excluding the Type 31 charge. Investegate

At 1,079p, Babcock would need a 41.5% rise to retest the 1,527p 52-week high. A move back to the June 29 intraday low would mean a 16.4% fall. That is the range left by a stock with cash returns on one side and a loss-making frigate contract on the other.

Mateusz Ługowik

Mateusz Ługowik is a senior markets reporter at Bez-kabli.pl, specializing in technology stocks, artificial intelligence and global financial markets. A graduate of the University of Gdańsk, he previously worked in investment research and market analysis. His coverage helps readers understand the key trends, companies and innovations influencing investors worldwide.

Stock Market Today

  • GSK Hits £80 Billion Mark as Oncology Push, New US Reimbursement Lift Shares
    July 7, 2026, 2:45 PM EDT. GSK shares climbed 1.01% to 2,003p in London, giving the pharma giant a market cap near £80 billion. The move puts the stock just above the median analyst 12-month target of 1,980p. Sentiment turned to GSK's oncology division, helped by optimism about double-digit earnings multiples and a 3.5% dividend yield. A key focus is Blenrep, its multiple myeloma treatment, which recently got a permanent U.S. reimbursement code, J9053. That provides stable payment and may lift Blenrep sales from £167 million in 2026 to £1.42 billion by 2031. While sales of HIV drugs including dolutegravir are set to sink on upcoming patent losses, the growing cancer drug pipeline is seen countering that before July 28 results. GSK's consensus model calls for turnover to rise 3.6% by 2031 and free cash flow to jump 34.7%, drawing investor attention.